Stocktoria
Kura Oncology, Inc. KURA
Kura Oncology, Inc. (KURA) earns a Piotroski F-score of 2/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $67.5M at a -412.9% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.801 |
| Retained earnings / assets | -1.59 |
| EBIT / assets | -0.411 |
| Equity / liabilities | 0.309 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| KURA | Kura Oncology, Inc. | 2/9 | -2.37 | — | +25.2% |
| SPRO | Spero Therapeutics, Inc. | 4/9 | -8.9 | 15.3 | +39.2% |
| AYTU | AYTU BIOPHARMA, INC | 4/9 | -8.14 | — | +1.8% |
| RMTI | ROCKWELL MEDICAL, INC. | 2/9 | -18.33 | — | -31.8% |
| ENTA | ENANTA PHARMACEUTICALS INC | 4/9 | -2.79 | — | -3.4% |
| VRDN | Viridian Therapeutics, Inc.DE | 2/9 | 2.72 | — | — |
| FBIO | Fortress Biotech, Inc. | 4/9 | -12.29 | 13.5 | +9.7% |
About Kura Oncology, Inc.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
FAQ
Is KURA financially healthy?
Kura Oncology, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does KURA pay a dividend?
No, Kura Oncology, Inc. does not currently pay a dividend.
How profitable is KURA?
In FY2025, Kura Oncology, Inc. had a net margin of -412.9% and a return on equity of -160.0%.
What is the analyst price target for KURA?
The average Wall-Street price target for Kura Oncology, Inc. is $31.17, about 213.5% above the recent price, from 12 analysts (consensus: strong buy).
Is KURA a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Kura Oncology, Inc.: a Piotroski F-score of 2/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.